These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37996401)

  • 21. Real world considerations for newly approved CGRP receptor antagonists in migraine care.
    Scuteri D; Tonin P; Nicotera P; Bagetta G; Corasaniti MT
    Expert Rev Neurother; 2022 Mar; 22(3):221-230. PubMed ID: 35240905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine.
    Caronna E; Starling AJ
    Neurol Clin; 2021 Feb; 39(1):1-19. PubMed ID: 33223077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
    Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
    Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.
    Edvinsson L
    J Intern Med; 2022 Oct; 292(4):575-586. PubMed ID: 35532284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of migraine with monoclonal antibodies.
    Serra López-Matencio JM; Gago-Veiga AB; Gómez M; Alañón Plaza E; Mejía GP; González-Gay MÁ; Castañeda S
    Expert Opin Biol Ther; 2022 Jun; 22(6):707-716. PubMed ID: 35502612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are antimigraine drugs that influence CGRP levels justified?
    Piechal A; Domitrz I; Kurkowska-Jastrzębska I; Mirowska-Guzel D
    Pharmacol Rep; 2019 Aug; 71(4):624-635. PubMed ID: 31181379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
    Edvinsson L; Warfvinge K
    Cephalalgia; 2019 Mar; 39(3):366-373. PubMed ID: 29020807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review.
    Takizawa T; Ihara K; Uno S; Ohtani S; Watanabe N; Imai N; Nakahara J; Hori S; Garcia-Azorin D; Martelletti P
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):951-967. PubMed ID: 37925645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A; Pozo-Rosich P
    Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sense of stopping migraine prophylaxis.
    Al-Hassany L; Lyons HS; Boucherie DM; Farham F; Lange KS; Marschollek K; Onan D; Pensato U; Storch E; Torrente A; Waliszewska-Prosół M; Reuter U;
    J Headache Pain; 2023 Feb; 24(1):9. PubMed ID: 36792981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Medications for the Treatment of Migraine.
    Ceriani CEJ; Wilhour DA; Silberstein SD
    Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological and small molecule strategies in migraine therapy with relation to the calcitonin gene-related peptide family of peptides.
    Edvinsson L; Edvinsson JCA; Haanes KA
    Br J Pharmacol; 2022 Feb; 179(3):371-380. PubMed ID: 34411289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.
    Wattiez AS; Sowers LP; Russo AF
    Expert Opin Ther Targets; 2020 Feb; 24(2):91-100. PubMed ID: 32003253
    [No Abstract]   [Full Text] [Related]  

  • 37. Mode and site of action of therapies targeting CGRP signaling.
    Labastida-Ramírez A; Caronna E; Gollion C; Stanyer E; Dapkute A; Braniste D; Naghshineh H; Meksa L; Chkhitunidze N; Gudadze T; Pozo-Rosich P; Burstein R; Hoffmann J
    J Headache Pain; 2023 Sep; 24(1):125. PubMed ID: 37691118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
    Dodick DW
    Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST; Wu JW
    Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
    De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S
    Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.